Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Pharm (Weinheim) ; 356(7): e2200661, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37196427

ABSTRACT

Ubiquitin-specific proteases represent a family of enzymes that catalyze the cleavage of ubiquitin from specific substrate proteins to regulate their activity. USP48 is a rarely studied USP, which has recently been linked to inflammatory signaling via regulation of the transcription factor nuclear factor kappa B. Nonetheless, a crystal structure of USP48 has not yet been resolved and potent inhibitors are not known. We screened a set of 14 commercially available USP inhibitors for their activity against USP48 and identified the USP2 inhibitor "ML364" as a candidate for further optimization. Using a ligand-based approach, we derived and synthesized a series of ML364 analogs. The IC50 concentrations of the new compounds to inhibit USP48 were determined in a deubiquitinylase activity assay by measuring the fluorescence intensity using tetra-ubiquitin rhodamine110 as substrate. A compound containing a carboxylic acid functionalization (17e) inhibited USP48 activity toward tetra-ubiquitin rhodamine110 with an IC50 of 12.6 µM. Further structure-based refinements are required to improve the inhibition activity and specificity.


Subject(s)
Signal Transduction , Ubiquitin-Specific Proteases , Structure-Activity Relationship , Ubiquitin-Specific Proteases/chemistry , Ubiquitin-Specific Proteases/metabolism , Transcription Factors , Ubiquitins
2.
J Med Chem ; 65(2): 1265-1282, 2022 01 27.
Article in English | MEDLINE | ID: mdl-35081715

ABSTRACT

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.


Subject(s)
Drug Design , Embryo, Nonmammalian/drug effects , NIMA-Related Kinase 1/antagonists & inhibitors , Polycystic Kidney Diseases/drug therapy , Pronephros/drug effects , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Animals , Embryo, Nonmammalian/enzymology , Polycystic Kidney Diseases/enzymology , Polycystic Kidney Diseases/pathology , Pronephros/embryology , Pronephros/enzymology , Zebrafish
SELECTION OF CITATIONS
SEARCH DETAIL
...